Upstream Processing

GettyImage/marchmeena29

“We need Big Pharma and we are getting Big Pharma,” says Dyadic

Dyadic confident Big Biopharma will move away from CHO cell reliance

By Dan Stanton

Dyadic International says a string of deals shows biopharma is beginning to embrace its low-cost and high-yielding – yet commercially unproven – fungus-based expression platform.

GettyImages/alexskopje

Compugen licenses Selexis cell line tech

By Dan Stanton

Compugen has selected Selexis’ SUREtechnology cell expression platform to generate high-performance research cell banks (RCBs) and support its antibody pipeline.

Follow us

Products

View more

Webinars